ANTCF

Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has sold four patent applications and all associated supporting data to Apollon Formularies PLC ("Apollon"), a UK based international pharmaceutical company listed for trading on the Aquis St... Read More...

TORONTO, Sept. 14, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"). On August 31, 2021, the Company anno... Read More...

TORONTO, Aug. 31, 2021 - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that it anticipates being late in filing its audited annual financial statements (the "Annual Financial Statements") and related management discussion and analysis ("MD&A") for the year ended April 30, 2021, by the prescribed dea... Read More...

TORONTO, July 14, 2021 - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that Dr. Winston De La Haye, Medical Director of the Aion International Center for Psychedelic Psychiatry in Jamaica (the "Center"), will be speaking at the international CanEx Psychedelics Summit in Montego Bay, Jamaica, takin... Read More...